rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GNBT - Generex Biotechnology - Deel 2

2.049 Posts
Pagina: «« 1 2 3 4 5 6 ... 103 »» | Laatste | Omlaag ↓
  3. [verwijderd] 21 juli 2006 22:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik zit ook grof in gnbt, als we zakken laten we dan maar even naar de 0,8 gaan, kan ik mooi bijkopen.

    Groet, Ronald

    (met een gemiddelde van $2,80).
  4. [verwijderd] 21 juli 2006 23:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik wacht ook geduldig af, heb al een keer een deel flink gecasht in de rit naar 5! Mijn gemiddelde is 0,96 dollarcent. Zodra die er onder komt koop ik er weer een gouden voorraad bij. Dit aandeel heeft me al heel wat "windeieren" gelegd! Meer dan mijn "dode INSM geld" Daar baal ik nog het meeste van!! GNBT long, het is nog een kwestie van tijd en dan gaat de lange weg omhoog beginnen!!

    Succes allemaal en laat je niet gek maken in deze rare, gespannen beursperiode!
  5. [verwijderd] 22 juli 2006 14:46

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Modbreak Koos (forum@iex.nl): Dit bericht is verwijderd. Kritiek op ons beleid (om grote threads voortaan een vervolg te geven in een deel 2) mag, maar om vervolgens in meerdere threads hierop te gaan spammen wordt ons te gortig.
  6. [verwijderd] 22 juli 2006 19:42

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    DieGroeneGigant schreef:

    Modbreak Koos (forum@iex.nl): Dit bericht is verwijderd. Kritiek op ons beleid (om grote threads voortaan een vervolg te geven in een deel 2) mag, maar om vervolgens in meerdere threads hierop te gaan spammen wordt ons te gortig.
    Vind je het echt makkelijk om in een draadje van duizenden pagina's iets terug te zoeken?
  7. [verwijderd] 22 juli 2006 20:45

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik zit in totaliteit ook dik in de winst, Ben al bijna 2 jaar in dit fonds aan het beleggen.

    Heb ook een keer heel leuk verdiend aan GTCB,maar dat durf ik niet echt aan op het moment.

    INSM is in mijn ogen ook erg koopwaardig als er nog een 0,15 vanaf gaat.
    Dan kan je bijna gegarandeerd een kwartje pakken op de korte termijn.

    Groet, Ronald.

  12. [verwijderd] 26 juli 2006 16:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    'Mogelijk vogelgriepvaccin in 2007'
    LONDEN (ANP) - Het Britse farmaciebedrijf GlaxoSmithKline (GSK) denkt volgend jaar een vaccin tegen het ook voor mensen gevaarlijke vogelgriepvirus H5N1 klaar te hebben voor massaproductie. Die verwachting is gebaseerd op onderzoek met vierhonderd vrijwilligers in België, aldus GSK woensdag.

    Het onderzochte vaccin bestond uit geïnactiveerde H5N1-virussen in combinatie met een nieuw adjuvans. Dat is een ingrediënt dat het immunologische afweersysteem stimuleert en de reactie op het vaccin vergroot. Uit meting van de aangemaakte antilichamen blijkt dat meer dan 80 procent van de proefpersonen voldoet aan de beschermingscriteria die gelden voor griepvaccins.

    Sinds 2003 zijn al 133 mensen aan vogelgriep overleden. GSK verwacht de komende maanden een aanvraag in te kunnen dienen voor toelating van het nieuwe vaccin. Ook andere bedrijven werken aan een H5N1-vaccin, aldus de BBC.
  13. [verwijderd] 26 juli 2006 18:06

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Generex Biotechnology Clinical Data Presented at Controlled Release Society Annual Meeting

    PrintE-mailDisable live quotesRSSDigg itDel.icio.usLast Update: 10:46 AM ET Jul 26, 2006

    TORONTO, Jul 26, 2006 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT : generex biotechnology cp del com
    News , chart, profile, more
    Last: 1.38+0.03+2.22%

    11:48am 07/26/2006

    Delayed quote dataAdd to portfolio
    Analyst
    Create alertInsider
    Discuss
    Financials
    Sponsored by:
    GNBT1.38, +0.03, +2.2%) , a leader in the area of buccal drug delivery, announced today that it made two poster presentations of clinical data at the 33rd Annual Meeting & Exposition of the Controlled Release Society in Vienna, Austria, July 22 - 26, 2006. The data relates to Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, and to Generex Metformin Gum, a proprietary alternative delivery format for metformin under development by Generex in collaboration with Fertin Pharma A/S.
    "The invitation to present our most recent data at this important international scientific symposium in the drug delivery sector is a gratifying recognition of our successes to date," said Anna Gluskin, the Company's President & Chief Executive Officer.
    The Controlled Release Society (CRS) ( www.controlledreleasesociety.org) is an international organization which serves 3,000 members from more than 50 countries. Two-thirds of the CRS membership represents industry and one-third represents academia and government. The CRS is a multi-disciplinary, international organization dedicated to improving quality of life by advancing science, technology, and education in the field of controlled delivery of bioactive substances.
    The first poster, entitled "Transfer From Short-Acting Insulin to Generex Oral-lyn(TM) at Lunchtime in 27 Juvenile Type-1 Diabetes Mellitus Patients: Importance of Diabetes Monitoring During the Stabilization Phase of a 6-Month Study," was authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President -- Medical Affairs.
    The poster reports observations during the initial phase of an on-going long-term study, taking place at the Institute of Endocrinology IEMYR in Quito, Ecuador with Dr. Guevara as principal investigator, performed in 24 adolescent and 5 young adult patients with Type-1 diabetes mellitus receiving subcutaneously (s.c.) injected twice daily (BID) glargine insulin as basal therapy and s.c. regular insulin before meals. The principal aim of the study is to compare the effects of replacing the lunchtime dose of s.c. regular insulin with Generex Oral-lyn given as a split dose before and after lunch.
    Since the study participants were referred to the institute in various degrees of metabolic control, it was necessary to stabilize them using standard therapy before replacement of the s.c. injection by Generex Oral-lyn at lunchtime. For this purpose, in addition to s.c. BID basal therapy and pre-prandial s.c. insulin, participants received enhanced nutritional advice and intense glucose monitoring for 21 days prior to replacement of the s.c. injected insulin by Generex Oral-lyn. The poster reports that the participants were metabolically stabilized in 21 days as documented by improvements in 6-point glucose daily profiles and protein glycation parameters that, in addition, showed correlation.
    The second poster, entitled "The Generex Metformin Gum: An Alternative Method for Delivery of Biguanides," was authored by Drs. Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President -- Medical Affairs.
    The poster reports the results of a clinical trial designed to compare pharmacokinetic profiles of metformin (used for the treatment of Type-2 diabetes mellitus in adults and children) administered by both the traditional manner (tablets) and by an alternative presentation (the Generex Metformin Gum product) that can be chewed thereby delivering metformin into the human body by way of the buccal cavity (i.e., the mouth).
    The conclusion of the study is that the Generex Metformin Gum displays a pharmacokinetic profile similar to that of the metformin tablets and therefore shows promise as an alternative method of delivering metformin. The Generex Metformin Gum presentation should avoid the significant adverse gastrointestinal side-effects often accompanying the use of metformin tablets thereby improving patient compliance. In addition, Generex Metformin Gum is expected to be an ideal companion product for the Company's oral insulin spray product, Generex Oral-lyn(TM). Generex Oral-lyn is designed to offer a safe, simple, fast, effective, flexible, and familiar alternative to subcutaneous injections of prandial insulin.
    About Generex
    Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
    For more information, visit the Generex Web site at www.generex.com
  21. Bel-chin 28 juli 2006 21:51

    • Bel-chin

      Lid sinds: 23 mrt 2005

      Laatste bezoek: 06 jun 2024

    • Aanbevelingen

      Ontvangen: 2

      Gegeven: 6

    •    Aantal posts: 188

    Press Release Source: Generex Biotechnology

    Generex Biotechnology Awarded Three New Patents
    Friday July 28, 10:00 am ET

    Company Expands Drug Delivery Platform Patent Portfolio in the United States and Japan

    TORONTO--(MARKET WIRE)--Jul 28, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), a leader in the area of buccal drug delivery, announced today that it has been awarded its first Japanese patents and a new United States patent expanding the Company's patent coverage for its oral insulin product, Generex Oral-lyn™.

    ADVERTISEMENT
    The Japanese patents, entitled "Aerosol Formulations for Buccal and Pulmonary Application" and "Pulmonary Drug Delivery," each contain claims relating to an improved delivery system for the administration of large-molecule pharmaceuticals, which may be administered by means of an aerosol into the mouth, for buccal or pulmonary application.

    The United States patent, entitled "Method for Administering Insulin to the Buccal Region," contains claims relating to an improved delivery system for the administration of large-molecule pharmaceuticals which may be administered through the oral and nasal membranes. The Company has now received a total of 19 patents from the United States Patent Office.

    "These are the first patents awarded to the Company in Japan, and we are happy to have extended our proprietary protection in a new jurisdiction and in a key commercial market," said Rose Perri, the Company's Chief Operating Officer.

    The Company currently holds an aggregate of 76 patents worldwide (19 of which are United States patents) and has an aggregate of 51 patent applications pending in various jurisdictions.

    About Generex

    Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.

    For more information, visit the Generex Web site at www.generex.com.

    Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

    Contact:

    Contact:
    Shayne Gilliatt
    Generex Biotechnology Corporation
    Phone: (800) 391-6755
    (416) 364-2551
    Andrew Hellman
    CEOcast, Inc.
    Phone: (212) 732-4300


    Source: Generex Biotechnology
2.049 Posts
Pagina: «« 1 2 3 4 5 6 ... 103 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.106
AB InBev 2 5.536
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.111
ABO-Group 1 23
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.836
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.815
Aedifica 3 926
Aegon 3.258 323.051
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.903
Agfa-Gevaert 14 2.062
Ahold 3.538 74.349
Air France - KLM 1.025 35.275
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.050
Alfen 16 25.212
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.787
AMG 971 134.281
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 495
Antonov 22.632 153.605
Aperam 92 15.053
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.802
Arcelor Mittal 2.034 320.952
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.599
ASML 1.766 109.869
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.881
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449